Kornimate/medical-research-clean huggingface dataset:
evaluation of the effectiveness of photodynamic therapy in the treatment of lesions of the lichen planus type in the oral mucosa and its diagnostics with the use of autofluorescence, in various wavelength ranges, in combination with the use of texture analysis and fractal dimension

Conditions: Oral Lichen Planus

Summary: lesions of the lichen planus type within the oral mucosa are now considered a potentially cancerous condition. one of the minimally invasive methods of treating these lesions is photodynamic therapy, and the gold standard in therapy is topical steroid administration

lichen planus shows an irregular shape, which is quite difficult to measure objectively, which is important in assessing the effectiveness of treatment. patients will be treated in protocol split mouth with the treatment of lesions on one cheek with a steroid (on an adhesive plaster) and on the other - photodynamic therapy with a foot sensitizer in the form of a methylene blue also on an adhesive plaster the treatment evaluation procedure will consist of taking a series of intraoral photographs. these photos will be taken at each visit. this procedure will involve taking pictures traditionally in "white" light and in the spectrum of 405 nm, 460 nm and 405 + 460 nm (using the unique feature of the prototype laser - emission of two wavelengths simultaneously) in order to induce autofluorescence of the mucosa and treated lesions to better visualize them a prospective, randomized, single-blind 12-week clinical trial of full contralateral split-mouth in patients with bilateral erythematous or erosive lichen planus in the mouth.on one side, the olp lesion eligible for treatment was subjected to photodynamic therapy using methylene blue in four sessions every 2 days. olp on the other side was treated with the administration of the steroid triamcinolone for 8 days the clinical evaluation of the evolution of olp eruptions was performed within 12 weeks of qualifying for treatment: at baseline, at the end of both treatments (day 8) and after the next 11 weeks

Eligibility criteria:
inclusion criteria: * histological diagnosis of olp * non smoker * no diabetes melitus * no hepatitis exclusion criteria: * diabetes melitus * hepatitis * occurrence dysplasia in the histopathological specimen; * use of lichenoid reaction inducing medication and presence of amalgam fillings nearby the lesions; * interventions for olp in the previous 12 weeks; * pregnant or breastfeeding women; * proved or suspected hypersensitivity to any of the chemicals used in the treatment

Keywords: photodynamic therapy
the atp project (antipsychotic-tep-psychosis)

Conditions: First Episose Psychosis; Metabolic Disease; Psychosis; Episode

Summary: the goal of this observational study is to the early impacts of psychosis and antipsychotic medications on brain metabolism in young adults recently diagnosed with a first episode of psychosis. the main question aims to evaluate the effect of 4 to 6 weeks of antipsychotic medication on brain metabolism measured by pet scan (cerebral uptake of 11c-acetoacetate + 18 fluorodeoxyglucose). participants will undergo a multimodal imaging protocol with other measures of psychopathology (e.g., cognition, depressive symptoms, etc.) and (metabolic marker, inflammation, etc).


Eligibility criteria:
inclusion criteria: * admission to the pep clinic in estrie, either outpatient or inpatient, according to the transdiagnostic pep model. * willingness to begin taking an ap (regardless of type and dose, or change in type and dose during the study). * ability to read and express themselves in french or english. * capable of understanding and signing consent. exclusion criteria: * pregnancy, childbirth in the last 6 months, or breastfeeding. * presence of a metallic object in the body that is incompatible with mri. * any use of aps for more than 2 continuous weeks in the past year and/or 6 weeks in a lifetime (except for aripiprazole if taken at less than 2.5 mg/day or quetiapine at less than 50 mg/day, regardless of duration or timing of the prescription). * the following comorbidities: psychosis + borderline or intellectual disability, autism spectrum disorder, substance use disorder with decompensation, psychosis induced by a medical condition, or psychosis induced by drug use or withdrawal. * type 1 diabetes. * uncontrolled acute suicidal ideation. * other conditions that could interfere with participation according to the judgment of the qualified physician.

Keywords: psychosis cerebral metabolism glucose ketone pet scan
effect of biological therapy on biomarkers in patients with untreated hepatitis c, metastatic melanoma, or crohn disease

Conditions: Melanoma

Summary: rationale: studying samples of blood from patients with cancer, hepatitis c, or crohn disease in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer and other diseases. purpose: this laboratory study is looking at the effect of biological therapy on biomarkers in patients with untreated hepatitis c, metastatic melanoma, or crohn disease.

objectives: * to determine how a variety of immune-modulating therapies (i.e., interferon alfa \[ifn-α\] in patients with untreated acute or chronic hepatitis c, anti-tumor necrosis factor in patients with active inflammatory bowel disease (i.e., crohn disease), and anticytotoxic t-lymphocyte antigen immunoglobulin in patients with metastatic melanoma) affect the tissue expression of indoleamine 2, 3 dioxygenase (ido), a major immune-regulatory mechanism. * to determine whether administration of pegylated inf-α in patients with untreated acute and chronic hepatitis c causes systemic changes in the ido pathway, as indicated by lowered serum tryptophan (trp) and elevated serum kynurenine (kyn). * to determine whether administration of ticilimumab (i.e., anti-ctla4 human monoclonal antibody cp-675,206) in patients with metastatic melanoma inhibits activation of the ido pathway as indicated by normal serum trp and normal serum kyn. * to determine whether administration of infliximab in patients with crohn disease inhibits activation of the ido pathway, as indicated by normal serum trp and normal serum kyn. outline: serum samples are collected from patients with hepatitis c and metastatic melanoma at baseline and at 3 to 4 weeks after treatment is initiated. previously collected samples from patients with crohn disease are also assessed at these time points. samples are analyzed for tryptophan and kynurenine levels via high-performance liquid chromatography. projected accrual: a total of 15 patients with untreated acute or chronic hepatitis c, 15 patients with metastatic melanoma, and 20 patients with crohn disease will be accrued for this study.

Eligibility criteria:
inclusion criteria: disease characteristics: * diagnosis of 1 of the following: * acute or chronic hepatitis c * receiving pegylated interferon alfa and ribavirin * metastatic melanoma * receiving ticilimumab * crohn disease * received prior infliximab exclusion criteria: * not specified patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: stage iv melanoma hepatitis c infection melanoma (skin) precancerous/nonmalignant condition
tumor registry of advanced renal cell carcinoma

Conditions: Renal Cell Carcinoma

Summary: the purpose of this registry is to record information of therapy reality of metastatic or locally advanced renal cell carcinoma by office-based medical oncologists in germany.

the rcc registry is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with mrcc. at inclusion, data in patient characteristics, comorbidities, tumor characteristics, and previous treatments are collected. during the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. patients are followed until death or for a maximum of 3 years.

Eligibility criteria:
inclusion criteria: * patients with metastatic or locally advanced renal cell carcinoma requiring therapy * start of first palliative therapy within 1 year before enrollment of patient to registry; since enrollment of 1000 patients: start of first palliative therapy within 4 weeks before enrollment exclusion criteria: -

Keywords: advanced renal cell carcinoma mrcc therapy-reality observation registry rcc arcc germany metastatic renal cell carcinoma renal cell carcinoma renal cell cancer sorafenib sunitinib interferon interleukin temsirolimus pazopanib cytokines vegf
psoriatic arthritis treat to target vs. usual care

Conditions: Psoriatic Arthritis (PsA)

Summary: canadian rheumatologists will be randomized to treat their participants with active psoriatic arthritis to a target (disease activity score \<2.6), or as per their routine care. the aim of this study is to determine whether treating to a target results in greater disease improvement than treating patients using routine care.

canadian rheumatologists will be randomized to treat their participants with active psoriatic arthritis to a target (disease activity score \<2.6), or as per their routine care. the aim of this study is to determine whether treating to a target results in greater disease improvement than treating patients using routine care.

Eligibility criteria:
inclusion criteria: * psoriatic arthritis as diagnosed by a rheumatologist and meeting acr classification criteria for psa or caspar criteria * the subject must provide written informed consent for participation in the study before any study specific procedures are performed * subject has 3 or more sjc on 28 joint count * age \>=18 exclusion criteria: * subject has a history of being non-compliant * serious concomitant illnesses that in the investigator's opinion negate ability to optimally treat the patient * if treating with tnf inhibitor, positive ppd \> 5mm who have not received inh for recommended course or untreated tb (ie cxr evidence of latent infection). usual screening is in place for standard of care. * pregnancy, breast-feeding or considering pregnancy over the next 12 months

Keywords: psoriatic arthritis randomized single blind treat to target
effect of body position changes on endotracheal tube cuff pressure in ventilated critically ill patients

Conditions: Mechanical Ventilation With Oral Intubation

Summary: the endotracheal tube secures free airway in patients undergoing surgical procedures or mechanical ventilation. the extraluminal airway needs to be sealed by a cuff. the cuff needs to be adequately inflated with air. the cuff pressure should be between 20 and 30 cm h2o. a cuff pressure in excess of the target range is associated with a risk of tracheal injury, whereas a cuff pressure below the lower limit includes a risk of micro-aspiration of subglottic secretions, with risk of subsequent ventilator-associated pneumonia. it is unknown whether the cuff pressure changes following changes in body position of the patient. the objective of this study is to investigate to which extent - if any - cuff pressures change after body position changes of the patient.


Eligibility criteria:
inclusion criteria are age 18 - 70 years, oral intubation with a taperguard evac endotracheal tube (covidien®), conventional mechanical ventilation, adequate sedation (richmond agitation-sedation scale -5) and analgesia (behavior pain scale 3 to 4). exclusion criteria are factors with potential influence on the cuff pressure or factors that disturbed the safety or well-being of the patient: pregnancy, palliative care, difficult intubation, decreased mobility of the neck, history of neck surgery, temperature of \ 37.5°c, morbid obesity (body mass index \>35) and every potential contra-indication for position changes such as unstable spinal cord injury or hemodynamic and/or respiratory instability.

Keywords: mechanical ventilation
ad sensor-based real-time diagnosis of adenovirus

Conditions: Adenovirus

Summary: to develop a real-time diagnostic technique with ad sensor for adenovirus detection, the investigators conduct a prospective clinical study. in comparison with results from direct sequencing of adenovirus, the investigators evaluate the performance of ad sensor , including reproducibility, sensitivity, specificity, and cross-reaction. the potential factors which may interfere with the results would be investigated. with such technique, the investigators hope to make early diagnosis and give adenovirus patients early treatment to reduce the complications and case-fatality rate.

1. sample acquirement： at national taiwan university hospital in taiwan, we will enroll patients who have adenovirus infection . we will take three throat swabs for each patient: one for viral isolation, one for rt-pcr and the last for the ad sensor - based real-time diagnosis. 2. ad sensor diagnosis： ad sensor (structural chip-based optosensing virus probing system), which is for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-adenovirus and its adenovirus antigen present in patients'and normal samples. 3. gold standard： viral isolation and rt-pcr

Eligibility criteria:
inclusion criteria: a: the patients with confirmed or suspected infection. b: the healthy person without disease. exclusion criteria: -

Keywords: adenovirus
a phase i clinical trial of a 13-valent pneumococcal conjugate vaccine and 14-valent pneumococcal conjugate vaccine in adults

Conditions: Pneumococcal Infections

Summary: the purpose of this study is to evaluate the safety and immunogenicity of lbve013 (pneumococcal 13-valent conjugate vaccine \[diphtheria crm197 protein\]) or lbve014 (pneumococcal 14-valent conjugate vaccine \[diphtheria crm197 protein\]) in healthy adults.


Eligibility criteria:
inclusion criteria: * healthy adult older than 19 years old and younger than 50 years old * a subject who was informed of the purpose, method, and efficacy of the clinical study and signed the written informed consent form exclusion criteria: * a subject who participated in other clinical studies within 3 months before screening * a subject who was vaccinated with other vaccines within 4 weeks before screening, or who is expected to receive other vaccination during the clinical study period * a subject with medical history of hypersensitive reactions (e.g. anaphylaxis) to the test drug or its ingredients * a subject who received immunoglobulin or blood-derived materials within 3 months before screening * a subject with immunologic function disorders including congenital or acquired immunodeficiency disorders * a subject who is receiving immunosuppressive therapy or drugs that can affect immunological reaction * a subject with pyrexia of over 38 celsius degrees on the day of the vaccination with the investigational products * a subject with medical history of invasive pneumococcal disease (ipd) or pneumonia caused by streptococcus pneumoniae * a subject who was vaccinated with any pneumococcal vaccine before screening * a subject who received the vaccine containing diphtheria toxoid within 6 months before screening (e.g. adult td vaccine)
ropinirole tablets in young patients with restless legs syndrome

Conditions: Restless Legs Syndrome

Summary: this is a two-period dose rising study of ropinirole immediate release in adolescent patients with restless legs syndrome (rls) in order to determine the starting dose for the ropinirole titration regimen for this age group. patients will receive two single doses unless poor tolerability is observed following the first dose.


Eligibility criteria:
inclusion criteria: * adolescent subjects diagnosed with probable or definite restless leg syndrome (rls). exclusion criteria: * subjects who require rls treatment during the daytime, suffer from other primary sleep disorders or are taking medication known to induce drowsiness, affect rls or sleep, or to induce or treat alertness, including methylphenidate.

Keywords: rls plms adolescent periodic limb movements of sleep ropinirole
sr-bi and antiviral treatment response in hcv

Conditions: Chronic Hepatitis C

Summary: the scavenger receptor type b class i (sr-bi) is a receptor for high-density lipoproteins (hdl) and one of entry factors for hepatitis c virus (hcv). the investigators aimed to examine the association of single nucleotide polymorphisms (snps) of the scarb1 gene, which encodes sr-bi, with virologic responses to pegylated interferon-based treatment in asian chronic hepatitis c (chc) patients.

1. purpose of study: to examine the impacts of single nucleotide polymorphisms (snps) relevant to sr-bi on chc patients. 2. study design to enroll 400 chc patients during a 3-year period 3. specify objectives of study when collecting extra specimen from participants collect blood samples for genomic dna to examine the sr-bi gene polymorphisms. 4. expected endpoints of treatment sustained virologic response (svr) means undetectable serum hcv rna levels 24 weeks after completion of antiviral therapy.

Eligibility criteria:
inclusion criteria: 1. naive to ifn treatment and other experimental antiviral or immunosuppressive therapy before enrollment. 2. serum alanine aminotransferase levels, at least, twice the upper limit of normal on two occasions within the previous 6 months. exclusion criteria: 1. positive for hepatitis b surface antigen 2. positive for human immunodeficiency virus antibody 3. had a known history or evidence of autoimmune liver disease, inheritable disorders, renal insufficiency, malignancy 4. had a history of daily alcohol consumption greater than 20 gram or active drug abuse.
a dose escalation trial of five fraction stereotactic radiation therapy for brain metastases

Conditions: Brain Metastases

Summary: this study looks at dose escalation for five fraction stereotactic radiotherapy for patients diagnosed with brain metastases with tumors 2.1-4.0 cm in diameter or 4.1-6.0 cm in diameter.

this study looks at dose escalation treatment in patients diagnosed with brain metastases. treatment involve five fraction stereotactic radiotherapy for patients with brain tumors 2.1-4.0 cm in diameter or 4.1-6.0 cm in diameter and dose escalation treatment is delivered only to the single largest tumor while all other tumors are treated with standard of care practices if they are present. a dose escalation schedule is proposed based on the monitoring of cns toxicity and tumor size of the largest tumor, given it falls into the parameters set on diameter.

Eligibility criteria:
inclusion criteria: * all patients must have histologically confirmed malignancy. * all patients must have imaging suggestive of one or more brain metastases. * karnofsky performance status (kps) ≥ 60 * age \> 18 years * patients must provide written informed consent to participate in the study. * patients must have less than or equal to 10 brain metastases as identified on brain mri. exclusion criteria: * history of surgical resection to the tumor of interest * history of radiation to the tumor of interest * history of previous whole brain irradiation * receipt of systemic therapy within one week of planned radiation treatment except for hormonal agents. * patient is unable to have mri or mri contrast. * inability to meet the appropriate normal tissue dose constraints secondary to tumor location should result in exclusion of the patient / tumor. * patients with a non-index tumor (second tumor) greater than 3 cm in diameter will be excluded.

Keywords: brain metastases stereotactic radiosurgery
durability of flexible ureteroscopes and causes of infection during flexible ureterorenoscopy

Conditions: Kidney Stones

Summary: this is an observational study in which data on consecutive patients who undergo ureterorenoscopy with the use of a flexible ureterorenoscope are collected. in total 20 new ureteroscopes are usedfrom olympus andfrom storz) to study the durability of the ureteroscopes and the possible microbiological load.

this is an observational study in which data on consecutive patients who undergo ureterorenoscopy with the use of a flexible ureterorenoscope are collected. in total 6 new ureteroscopes are used (3 from olympus and 3 from storz) to study the durability of the ureteroscopes and the possible microbiological load. before the procedure is started the endoscope is tested for its microbiological load in two different ways:1. shake the tip of the flexible ureterorenoscope 5 seconds in a sterile container filled with 10 cc of nacl 0.9% 2. flush the working channel of the ureterorenoscope with 10 cc of nacl 0.9% and collect the sample in a sterile container. after the procedure is finished, the endoscope is tested for its microbiological load in two different ways: 1. shake the tip of the flexible ureterorenoscope 5 seconds in a sterile container filled with 10 cc of nacl 0.9% 2. flush the working channel of the ureterorenoscope with 10 cc of nacl 0.9% and collect the sample in a sterile container. transfer all samples to the lab as soon as possible but at least within four hours after collecting the samples. as for the clinical efficacy during each procedure a detailed questionnaire about the use of each ureteroscope is filled out. this includes the ease of use making mention on quality of the image, torque, flexibility and durability. data will be collected through electronic case report forms (ecfrs), with use of an online data management system (dms).

Eligibility criteria:
inclusion criteria: * patient presented with a diagnosis to undergo a ureterorenoscopy using a flexible ureterorenoscope * over 18 years * has signed informed consent * the patient is being treated with the designated flexible ureterorenoscope

Keywords: microbiological burden kidney stone durability of flexible endoscopes
impact of abbvie care patient support program on clinical, health economic and patient reported outcomes, in crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, psoriasis and axial spondyloarthritis, in the portuguese national health service

Conditions: Crohn's Disease; Ulcerative Colitis (UC); Rheumatoid Arthritis (RA); Psoriatic Arthritis; Psoriasis; Ankylosing Spondylitis (AS); Non-radiographic Axial Spondyloarthritis

Summary: this study aims to evaluate the impact of abbvie care 2.0 on adalimumab's compliance, patient reported outcomes and utilization of health resources over 12 months.


Eligibility criteria:
inclusion criteria: * diagnosed with crohn's disease (cd), ulcerative colitis (uc), rheumatoid arthritis (ra), psoriatic arthritis (psa), axial spondyloarthritis (spa) or psoriasis (pso) according to the treating physician * adalimumab was started within 1 month prior to study enrollment * adalimumab was introduced based on current clinical practice criteria (i.e., the prescription of adalimumab was clearly separated from the decision to include the participants in this study) * no prior record of adalimumab treatment * adalimumab was administered according to product label * naïve or previously experienced with biologic treatment * participant is able and willing to provide written authorization to disclose and use personal health information (informed consent), and to agree that data will be collected and provided to abbvie abbvie care 2.0 cohort-specific inclusion criteria: * initiated the abbvie care program within the first month after starting adalimumab. exclusion criteria: * definitive discontinuation of adalimumab before being proposed to participate in the study * participated in any clinical experimental research within the 2 months prior to enrollment * pregnant or breastfeeding female participants * participant not able or not willing to comply with the requirements of this study protocol.

Keywords: adalimumab humira® abbvie patient care support program psoriasis axial spondyloarthritis rheumatoid arthritis ulcerative colitis